Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

NCT01783938 PHASE2 COMPLETED Results posted

The purpose of this study is to evaluate the safety and efficacy of a sequential combination therapy of Nivolumab and Ipilimumab

Details

Lead sponsor	Bristol-Myers Squibb
Phase	PHASE2
Status	COMPLETED
Enrolment	138
Start date	Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Aug 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced or Metastatic Melanoma

Interventions

• Nivolumab
• Ipilimumab

Countries

United States